Day One | Targeted Therapies for Patients of All Ages | Home

Now FDA approved
in the U.S.

Read the press release

Ready to make an impact.

We are working hard to bring novel targeted therapies to children with brain tumors and potentially others who can benefit.

Recent press releases

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Read More

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Read More

Day One Announces Two New Appointments to Board of Directors

Read More

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.

Yes No